A specialty pharmaceutical company focused on niche drug delivery technologies and products – Inyx, Inc. (OTC: IYXI) – has recently signed an agreement with Plethora Solutions Holdings plc (SEA: PLE) - an emerging U.K. specialty pharmaceutical company – for the manufacture of topical HFA aerosol product used in the treatment of premature ejaculation (PE) for Phase III clinical trial in the United States.
The said production will be conducted at Inyx USA's FDA-approved site in Puerto Rico.
PE is a medically recognized condition defined as "persistent or recurrent ejaculation with minimal sexual stimulation before, upon or shortly after penetration, and before the person wishes it."
It (PE) is the MOST common form of sexual dysfunction in men, with some 20 million men in the US experiencing it (according to the American Medical Association).
Currently, there is no approved pharmaceutical therapy for PE.
Source: Inyx, Inc.
[photo credit: Plethora Solutions]
.jpg)
Comment Preview